Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy.
Company profile
Ticker
ENVB
Exchange
Website
CEO
Brent Kelton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERI Holdings, Inc., SPATIALIZER AUDIO LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
Jay Pharma Inc. • 1306432 B.C. Unlimited Liability Company • Enveric Biosciences Canada, Inc. • MagicMed USA, Inc. • Akos Biosciences, Inc. • Enveric Therapeutics Pty. Ltd. • Delaware, USA • Adelaide, Australia ...
IRS number
954484725
ENVB stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
7 Jun 23
8-K
Regulation FD Disclosure
6 Jun 23
8-K
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
5 Jun 23
8-K
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
30 May 23
8-K
Termination of a Material Definitive Agreement
24 May 23
8-K
Regulation FD Disclosure
24 May 23
8-K
Regulation FD Disclosure
22 May 23
8-K
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
19 May 23
8-K
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
18 May 23
Latest ownership filings
4
Kevin Michael Coveney
14 Mar 23
3
Kevin Michael Coveney
14 Mar 23
SC 13G
AdvisorShares Trust
14 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
SC 13G
Hudson Bay Capital Management LP
7 Feb 23
SC 13G/A
ALPHA CAPITAL ANSTALT
6 Feb 23
4
Peter J. Facchini
27 Jan 23
4
Jillian Marie Hagel
27 Jan 23
4
Avani Kanubaddi
27 Jan 23
4
Joseph Edward Tucker
27 Jan 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 4 |
| Closed positions | 1 |
| Increased positions | 6 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 365.40 mm |
| Total shares | 5.92 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| TOP Invest | 2.30 mm | $13.61 mm |
| Stefansky David | 1.15 mm | $6.80 mm |
| TAF | 934.26 k | $3.98 mm |
| Chex Associates | 882.79 k | $5.23 mm |
| Intracoastal Capital | 206.14 k | $0.00 |
| AdvisorShares Trust | 116.30 k | $0.00 |
| AdvisorShares Investments | 116.30 k | $238.41 mm |
| Hudson Bay Capital Management | 110.36 k | $0.00 |
| Alpha Capital Anstalt | 47.03 k | $0.00 |
| BLK Blackrock | 29.58 k | $61.52 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Mar 23 | Kevin Michael Coveney | Common Stock | Grant | Acquire A | No | No | 0 | 26,500 | 0.00 | 26,500 |
| 25 Jan 23 | Avani Kanubaddi | Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 48,346 |
| 25 Jan 23 | Joseph Edward Tucker | Common Stock | Grant | Acquire A | No | No | 0 | 44,000 | 0.00 | 74,196 |
| 25 Jan 23 | Peter J. Facchini | Common Stock | Grant | Acquire A | No | No | 0 | 17,000 | 0.00 | 40,865 |
News
Enveric Stock Trading Higher On Notice Of Allowance For Patent Application For Its Carboxylated Psilocybin Derivatives
5 Jun 23
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
31 May 23
12 Health Care Stocks Moving In Tuesday's Intraday Session
30 May 23
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
30 May 23
12 Health Care Stocks Moving In Thursday's Intraday Session
25 May 23
Press releases
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
7 Jun 23
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
5 Jun 23
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
30 May 23
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
24 May 23
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
22 May 23